Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ImmunityBio, Inc. Director's Dealing 2016

Jul 28, 2016

31529_dirs_2016-07-28_9377e5d6-eddb-4310-8356-3c1108faa8dd.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NantKwest, Inc. (NK)
CIK: 0001326110
Period of Report: 2016-07-27

Reporting Person: Simon Barry J. (Director, President and COO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-07-27 Common Stock M 185150 $0.00 Acquired 3444228 Direct
2016-07-27 Common Stock F 79322 $6.89 Disposed 3364906 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2016-07-27 Restricted Stock Units $ M 185150 Disposed Common Stock (185150) Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of NantKwest, Inc. common stock.

F2: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 50% of the RSUs vested on July 27, 2015, and 50% of the RSUs will vest on July 27, 2016.